

CITATION REPORT

List of articles citing

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial

DOI: 10.1161/circgenetics.111.961144

Circulation: Cardiovascular Genetics, 2012, 5, 257-64.

Source: <https://exaly.com/paper-pdf/52420962/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
219	RHOA is a modulator of the cholesterol-lowering effects of statin. 2012 , 8, e1003058		24
218	Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 676-85		30
217	Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. 2012 , 32, 2541-6		78
216	Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. 2012 , 126, 2739-48		374
215	Predicting response to statins by pharmacogenetic testing. <i>Pharmacogenomics</i> , 2012 , 13, 1223-5	2.6	5
214	Association of MYLIP rs3757354 SNP and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations. 2012 , 11, 141		5
213	Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 230-42	6.1	29
212	Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 113-25	6.1	102
211	Pharmacogenetics and cardiovascular disease--implications for personalized medicine. 2013 , 65, 987-1009		93
210	Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. 2013 , 10, 625-42		119
209	Lipid-lowering pharmacogenomics in Chinese patients. 2013 , 11, 985-97		2
208	Plaque Stability and the Southern European Paradox. 2013 , 66, 56-62		
207	Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. 2013 , 168, 3071-3		17
206	Plaque stability and the southern European paradox. 2013 , 66, 56-62		22
205	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. <i>Pharmacogenomics</i> , 2013 , 14, 1283-94	2.6	75
204	Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. 2013 , 165, 1008-14		66
203	Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?. 2013 , 15, 295		61

202	Regulatory Perspective on Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. 2013 , 39-71		
201	Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. 2013 , 13, 79-85		2
200	Pharmacogenomics of lipid-lowering therapies. <i>Pharmacogenomics</i> , 2013 , 14, 981-95	2.6	18
199	Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. 2013 , 33, 447-60		4
198	Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. 2013 , 34, 1292-7		43
197	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 400-8		124
196	Statins and lipid metabolism: an update. 2013 , 24, 221-6		24
195	Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. 2013 , 23, 518-25		19
194	Circulation Editors Picks. 2013 , 128,		
193	To replicate or not to replicate: the case of pharmacogenetic studies: Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 413-8; discussion 418		24
192	Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. 2013 , 34, 982-92		78
191	Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. 2013 , 83, 919-29		32
190	International Transporter Consortium commentary on clinically important transporter polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 23-6	6.1	128
189	Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. 2013 , 9, 287-306		25
188	Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation. 2014 , 15, 460		23
187	Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. <i>Pharmacogenomics</i> , 2014 , 15, 1091-104	2.6	15
186	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. 2014 , 5, 5068		160
185	The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia. 2014 , 24, 548-55		16

184	Pharmacogenomics of statin therapy: any new insights in efficacy or safety?. 2014 , 25, 438-45		11
183	Ancestry and other genetic associations with plasma PCSK9 response to simvastatin. 2014 , 24, 492-500		10
182	The pharmacology of statins. 2014 , 88, 3-11		295
181	Targeting inflammation: impact on atherothrombosis. 2014 , 7, 9-18		12
180	How low an LDL-C should we go with statin therapy?. 2014 , 16, 388		4
179	Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. 2014 , 545, 124-32		11
178	Genome-wide family-based linkage analysis of exome chip variants and cardiometabolic risk. 2014 , 38, 345-52		14
177	Liver X receptors in lipid metabolism: opportunities for drug discovery. 2014 , 13, 433-44		385
176	Pharmacogenomics, lipid disorders, and treatment options. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 36-47	6.1	20
175	Anti-inflammatory therapies for cardiovascular disease. 2014 , 35, 1782-91		355
174	Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 314-20	6.1	12
173	The pharmacogenomics of statins. 2014 , 88, 99-106		30
172	The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice. 2014 , 20, 910-918		60
171	Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. 2014 , 10, 51-65		22
170	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. 2014 , 64, 485-94		372
169	LDL cholesterol: controversies and future therapeutic directions. 2014 , 384, 607-617		181
168	Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. 2014 , 37, 481-500		4
167	In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHarmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study. 2014 , 235, 58-64		6

166	Dietary modulators of statin efficacy in cardiovascular disease and cognition. 2014 , 38, 1-53	9
165	Resistance and intolerance to statins. 2014 , 24, 1057-66	132
164	Polymorphisms of Drug Transporters and Clinical Relevance. 2014 , 389-407	1
163	Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. 2014 , 3, e124	56
162	Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia. 2015 , 14, 107	3
161	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2015 ,	4
160	Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. 2015 , 94, e881	4
159	Novel genes in LDL metabolism--a comprehensive overview. 2015 , 26, 179-87	8
158	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. 2015 , 10, e0122414	9
157	Association between SLCO1B1 521 T>C and 388 A>G Polymorphisms and Statins Effectiveness: A Meta-Analysis. 2015 , 22, 796-815	10
156	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. 2015 , 31, 221-8	16
155	Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. 2015 , 184, 772-795	15
154	Interaction between Common Genetic Variants and Total Fat Intake on Low-Density Lipoprotein Peak Particle Diameter: A Genome-Wide Association Study. 2015 , 8, 44-53	14
153	Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. 2015 , 36, 3404-12	264
152	Genetic and immunologic susceptibility to statin-related myopathy. 2015 , 240, 260-71	26
151	Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. 2015 , 25, 8-18	17
150	Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. 2015 , 50, 447-58	4
149	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 688-95	3

148	SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. <i>Pharmacogenomics</i> , 2015 , 16, 449-58	2.6	14
147	Direct sequencing for comprehensive screening of LDLR genetic polymorphisms among five ethnic populations. 2015 , 37, 247-255		1
146	Is personalized medicine a dream or a reality?. 2015 , 52, 1-11		20
145	Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. 2016 , 48, 867-76		34
144	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. 2016 , 53, 835-845		28
143	Once and for all, LXRE and LXRE are gatekeepers of the endocrine system. 2016 , 49, 31-46		36
142	Response to the letter "No evidence to support high-intensity statin in Chinese patients with coronary heart disease". 2016 , 209, 192-3		
141	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. <i>Pharmacogenomics</i> , 2016 , 17, 583-91	2.6	8
140	RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 223-30		17
139	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 253, 261-344		519
138	Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. 2016 , 72, 1471-1478		11
137	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. 2016 , 37, 2999-3058		1781
136	Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. <i>Pharmacogenomics</i> , 2016 , 17, 2015-2024	2.6	2
135	Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug. 2016 , 20, 498-509		9
134	Linking Common Polymorphisms to Statin Responsiveness at the MYLIP Locus. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 206-9		
133	Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. 2016 , 7, 11122		335
132	Pharmacogenomic approaches to lipid-regulating trials. 2016 , 27, 557-562		4
131	Statins and Their Effect on PCSK9-Impact and Clinical Relevance. 2016 , 18, 46		17

130	Serum biomarkers and source of inflammation in acute coronary syndromes and percutaneous coronary interventions. 2016 , 17, 119-28	12
129	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. 2016 , 18, 24	15
128	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. 2016 , 118, 607-19	22
127	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. 2016 , 37, 1373-9	125
126	The genetics of drug efficacy: opportunities and challenges. 2016 , 17, 197-206	72
125	Seventeen years of statin pharmacogenetics: a systematic review. <i>Pharmacogenomics</i> , 2016 , 17, 163-80	2.6 37
124	The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. 2017 , 17, 204-208	21
123	Personalized medicine: Genetic risk prediction of drug response. 2017 , 175, 75-90	26
122	Myotoxicity of statins: Mechanism of action. 2017 , 175, 1-16	80
121	En route to precision medicine through the integration of biological sex into pharmacogenomics. 2017 , 131, 329-342	21
120	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2017 , 4, CD011748	57
119	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017 , 24, 313-329	2.9 7
118	Replication and fine-mapping of genetic predictors of lipid traits in African-Americans. 2017 , 62, 895-901	7
117	The APOE ϵ allele is associated with increased plasma apolipoprotein E levels in patients with coronary artery disease. 2017 , 59, e235-e239	0
116	Precision medicine to change the landscape of cardiovascular drug development. 2017 , 2, 337-343	
115	Proprotein-Convertase Subtilisin-Kexin Type 9 and Low-Density Lipoprotein Receptor Genotype Distribution and Statin Association in Filipino American Women. 2017 , 1, 108-115	
114	Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. 2017 , 37, 1172-1190	14
113	Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. 2017 , 13, 973-983	16

112	Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		2
111	Statin therapy: time for a precision medicine approach?. 2017 , 2, 187-192		0
110	Systems Pharmacology Dissection of Cholesterol Regulation Reveals Determinants of Large Pharmacodynamic Variability between Cell Lines. 2017 , 5, 604-619.e7		13
109	PharmGKB summary: very important pharmacogene information for ABCG2. 2017 , 27, 420-427		14
108	Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. 2017 , 17, 222-229		7
107	A genetic risk score is significantly associated with statin therapy response in the elderly population. 2017 , 91, 379-385		10
106	Genetic polymorphisms as predictive markers for statin therapy: a route to improved cardiovascular patient outcomes?. 2017 , 10,		1
105	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. 2017 , 38, 3569-3575		25
104	Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. 2017 , 11, 1135-1146		19
103	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. 2017 , 18,		21
102	Racial Differences in the Cholesterol-Lowering Effect of Statin. 2017 , 24, 19-25		47
101	Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. 2017 , 11, 1409-1416		20
100	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 803-817	6.1	60
99	Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. 2018 , 117, 55-61		16
98	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. 2018 , 39, 4150-4158		49
97	Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. 2018 , 11, 112-122		24
96	Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments. 2017 , 20, 4		78
95	Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. 2018 , 11, e002043		11

94	Prediction of response to lipid-lowering treatments. 2018 , 3, 335-337	
93	Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. 2018 , 70 Suppl 3, S120-S125	9
92	KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment. 2018 , 13, e0205430	8
91	An update on efflux and uptake transporters as determinants of statin response. 2018 , 14, 613-624	15
90	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. 2018 , 20, 56	2
89	Pharmacogenetics of Antidiabetic Drugs. 2018 , 83, 361-389	9
88	Statin Responses in Chinese Patients. 2018 , 25, 199-202	18
87	Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia. 2018 , 32, e22566	7
86	Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes. 2018 , 11, e001992	22
85	ZNF542P is a pseudogene associated with LDL response to simvastatin treatment. 2018 , 8, 12443	4
84	Liver X receptors in lipid signalling and membrane homeostasis. 2018 , 14, 452-463	213
83	Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. 2018 , 20, 60	4
82	An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. 2019 , 19, 240-248	5
81	Pharmacogenetics of statins treatment: Efficacy and safety. 2019 , 44, 858-867	17
80	IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation. 2019 , 39, 2468-2479	10
79	Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. 2019 , 15, 897-911	5
78	Gut Microbiome and Response to Cardiovascular Drugs. 2019 , 12, 421-429	33
77	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205	259

76	Principles of Pharmacogenomics. 2019 , 1-53	2
75	A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study. 2019 , 12, 26	3
74	Pharmacoeigenetics of Statins. 2019 , 817-825	
73	Current pharmacotherapeutic options for primary dyslipidemia in adults. 2019 , 20, 1277-1288	14
72	Group IIA Secretary Phospholipase A, Vascular Inflammation, and Incident Cardiovascular Disease. 2019 , 39, 1182-1190	12
71	Statins: Are they really all the same?. 2019 , 17, 211-212	
70	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial. 2019 , 30, 143-149	1
69	A phenome-wide association study (PheWAS) in the Population Architecture using Genomics and Epidemiology (PAGE) study reveals potential pleiotropy in African Americans. 2019 , 14, e0226771	8
68	The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article). 2019 , 98, e18510	2
67	Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy. 2019 , 2019, 3824823	3
66	Current status of familial hypercholesterolemia in Chinese populations. 2019 , 30, 94-100	6
65	A meta-analysis of Italian and Estonian individuals shows an effect of common variants in on blood apoB levels. 2019 , 13, 931-940	
64	Pharmacogenomics. 2019 , 445-486	
63	Oxydative stress markers and cytokine levels in rosuvastatin-medicated hypercholesterolemia patients. 2019 , 44, 530-538	
62	Important drug-micronutrient interactions: A selection for clinical practice. 2020 , 60, 257-275	19
61	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188	2236
60	Genetic contribution to lipid target achievement with statin therapy: a prospective study. 2020 , 20, 494-504	2
59	Carotid Intima-Media Thickness: Novel Loci, Sex-Specific Effects, and Genetic Correlations With Obesity and Glucometabolic Traits in UK Biobank. 2020 , 40, 446-461	7

58	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2020 , 10, CD011748	12
57	Gender Differences in Drug Therapy. 2020 , 547-570	
56	Genetic variants modulate gene expression statin response in human lymphoblastoid cell lines. 2020 , 21, 555	4
55	Ethnogeographic and inter-individual variability of human ABC transporters. 2020 , 139, 623-646	21
54	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. 2020 , 16, 371-385	6
53	The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. 2020 , 5, 1	7
52	Integrating DNA sequencing and transcriptomic data for association analyses of low-frequency variants and lipid traits. 2020 , 29, 515-526	4
51	Different Statin Effects of ST-elevation Versus Non-ST-Elevation Acute Myocardial Infarction After Stent Implantation. 2020 , 359, 156-167	1
50	Pleiotropy-Based Decomposition of Genetic Risk Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. 2020 , 106, 646-658	6
49	Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network. 2021 , 45, 4-15	5
48	Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. 2021 ,	0
47	Hepatic transporter-mediated pharmacokinetic drug-drug interactions: Recent studies and regulatory recommendations. 2021 , 42, 45-77	0
46	Personalized medicine in lipid-modifying therapy. 2021 , 18, 185-203	0
45	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. 2021 ,	9
44	Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis. 2021 , 11,	0
43	Identifying genetic modulators of statin response using subject-derived lymphoblastoid cell lines. <i>Pharmacogenomics</i> , 2021 , 22, 413-421	2.6 0
42	Habitual coffee intake and plasma lipid profile: Evidence from UK Biobank. 2021 , 40, 4404-4413	1
41	High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in East Asian patients undergoing percutaneous coronary intervention: A meta-analysis of fifteen randomized controlled trials. 2021 , 100, e26278	0

40	Genomewide Association Studies in Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 637-648	6.1	5
39	Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. 2021 , 1		3
38	Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia. 2021 , 11,		1
37	Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study. <i>Frontiers in Genetics</i> , 2021 , 12, 728526	4.5	1
36	Cardiovascular Disease Pharmacogenomics. 2013 , 417-433		1
35	Electronic health records to facilitate continuous detection of familial hypercholesterolemia. 2020 , 310, 83-87		3
34	The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease. 2019 , 30, 192-197		5
33	LPAandAPOEare associated with statin selection in the UK Biobank.		0
32	SLCO1B1 Polymorphisms and Statin-Induced Myopathy. 2013 , 5,		33
31	A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. 2015 , 10, e0120758		118
30	PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes. 2020 , 17, 138-146		3
29	Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. 2021 , 8,		1
28	Gender Differences in Drug Therapy. 2019 , 1-24		
27	Statins in real clinical practice: current guidelines, possibilities of new schemes for their use. 2019 , 22, 86		
26	[The problem of safety of lipid-lowering therapy]. 2019 , 59, 13-26		1
25	Pharmacogenomics in Cardiovascular Diseases. 2020 , 21-38		
24	Genome-wide association of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) plasma levels in the ELSA-Brasil study.		
23	Genome-Wide Association Study And Polygenic Risk Scores Of Serum Dheas Levels In A Chilean Children Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	0

22	Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer. 2013 , 4, 183-92		1
21	THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH. 2016 , 21, 369-80		4
20	Mechanisms and genetics of drug transport. 2022 , 213-239		0
19	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension.. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022 , 1	2.9	0
18	Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.. <i>Pharmacogenomics</i> , 2021 ,	2.6	0
17	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	9
16	LncRNAs and Cardiovascular Disease.. <i>Advances in Experimental Medicine and Biology</i> , 2022 , 1363, 71-95	3.6	0
15	Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.. <i>Pharmacogenomics and Personalized Medicine</i> , 2022 , 15, 119-130	2.1	
14	Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.. <i>Endocrinology, Diabetes and Metabolism</i> , 2022 , e00326	2.7	
13	Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers.. <i>Frontiers in Nutrition</i> , 2022 , 9, 850318	6.2	2
12	ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP). 2022 , 235-256		
11	Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	
10	Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	2
9	Correlation between genetic polymorphisms in apolipoprotein E and atrial fibrillation. <i>Revista Portuguesa De Cardiologia</i> , 2022 ,	1	0
8	IDOL deficiency inhibits cholesterol-rich diet-induced atherosclerosis in rabbits.		
7	Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects. <i>Frontiers in Genetics</i> , 13,	4.5	
6	Inter-Individual Variability in Lipid Response: A Narrative Review. <i>American Journal of Medicine</i> , 2022 ,	2.4	
5	A comprehensive pharmacogenomic study indicates roles for SLCO1B1 , ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.		0

- 4 Association of Physical Activity With Bioactive Lipids and Cardiovascular Events. **2022**, 131, 1
- 3 Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. **2022**, 146, 1225-1242 0
- 2 The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. **2023**, 2, 122-164 0
- 1 Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease. **2023**, 11, 0